Next-Generation CDK Inhibitor Design and Synthesis Platform

A machine learning-driven platform for identifying, synthesizing, and optimizing novel CDK inhibitor compounds with improved efficacy and selectivity, enabling personalized cancer treatment and overcoming limitations of existing CDK inhibitors.

The original patent disclosed a series of 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors. However, these compounds have limited efficacy and selectivity, leading to undesirable side effects and reduced therapeutic outcomes. The new inventive concept addresses these limitations by leveraging machine learning and artificial intelligence to design and synthesize next-generation CDK inhibitors with improved properties.

The inventive concept comprises a system for identifying optimal CDK inhibitor compounds using a machine learning model trained on a dataset of pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds. The system further includes a prediction module for generating a ranking of said compounds based on their predicted efficacy and selectivity. Additionally, the inventive concept encompasses a method for synthesizing next-generation CDK inhibitors by identifying a lead compound using a machine learning model and modifying it through iterative rounds of molecular editing and testing to optimize its efficacy and selectivity. The inventive concept also includes a pharmaceutical composition comprising a CDK inhibitor compound synthesized using a machine learning-assisted design approach, as well as a computer-implemented method for designing novel CDK inhibitor compounds using generative adversarial networks and machine learning models. Furthermore, the inventive concept encompasses a system for personalized cancer treatment, comprising a database of patient-specific genomic data, a machine learning model for predicting the efficacy of different CDK inhibitor compounds for a given patient, and a recommendation module for generating a personalized treatment plan based on said predictions.

The new inventive concept introduces a paradigm shift in CDK inhibitor design and synthesis by integrating machine learning and artificial intelligence to overcome the limitations of existing CDK inhibitors. The use of machine learning models to predict efficacy and selectivity, as well as the incorporation of generative adversarial networks for molecular design, represents a novel and non-obvious approach that distinguishes the inventive concept from the original patent.

Alternative embodiments of the inventive concept may include the use of different machine learning models or algorithms, such as deep learning or reinforcement learning, to optimize CDK inhibitor design and synthesis. Variations of the inventive concept may also include the integration of additional data sources, such as genomic or proteomic data, to further personalize cancer treatment. Furthermore, the inventive concept could be adapted for the design and synthesis of inhibitors targeting other kinases or protein targets.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the development of personalized cancer therapies. The market for CDK inhibitors is expected to grow significantly in the coming years, and the inventive concept's ability to design and synthesize novel compounds with improved efficacy and selectivity positions it for a substantial share of this market.